JFL Life Sciences Ltd

Shares of JFL Life Sciences Ltd plunged to their lower circuit limit on 2 Feb 2026, closing at ₹10.45, marking a maximum daily loss of 5.0%. The stock faced intense selling pressure, with panic selling dominating trade and leaving significant unfilled supply at the close. This sharp decline comes amid deteriorating investor sentiment and a weak sectoral backdrop.

JFL Life Sciences Ltd surged to hit its upper circuit price limit on 30 Jan 2026, registering a maximum daily gain of 4.78% amid robust buying interest and heightened investor participation. The stock closed at ₹10.95, marking a notable outperformance against its sector and the broader market indices.

JFL Life Sciences Ltd has demonstrated a marked turnaround in its financial performance for the quarter ended December 2025, posting robust revenue growth and margin expansion that contrasts sharply with its recent historical trends. Despite persistent headwinds in the broader market and a challenging sector environment, the pharmaceutical and biotechnology company has improved its financial trend from flat to positive, signalling potential stabilisation and renewed investor interest.

JFL Life Sciences Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹33.00 crores, posted net profit of ₹1.97 crores in Q2 FY26, marking a sequential surge of 162.67% quarter-on-quarter but declining 35.86% year-on-year. The stock, trading at ₹10.45 as of January 29, 2026, gained 4.50% in the latest session but remains under severe pressure, having plunged 53.96% over the past year and trading near its 52-week low of ₹10.00.

JFL Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

JFL Life Sciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, plunged to its lower circuit price limit on 21 Jan 2026, closing at a new 52-week and all-time low of ₹10.1. The stock witnessed intense selling pressure, resulting in a maximum daily loss of 4.72%, significantly underperforming its sector and broader market benchmarks.

JFL Life Sciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 6 Jan 2026 as it hit its lower circuit limit, closing at ₹11.75, down 4.86% from the previous close. The stock’s plunge reflects intense selling pressure and a marked deterioration in investor sentiment, underscored by a significant drop in trading volumes and unfilled supply on the order books.

Shares of JFL Life Sciences Ltd plunged to their lower circuit limit on 5 Jan 2026, closing at ₹12.35 after a sharp 5.0% decline. The stock witnessed intense selling pressure, with volumes drying up and panic selling dominating trade, signalling heightened investor concern amid a deteriorating outlook for the micro-cap pharmaceutical company.

JFL Life Sciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed intense selling pressure on 31 Dec 2025, hitting its lower circuit limit. The stock closed at ₹12.50, marking a maximum daily loss of 3.73%, significantly underperforming the sector and broader market indices. This sharp decline reflects mounting investor concerns amid falling participation and unfilled supply, signalling a potential shift in market sentiment towards the company.

Shares of JFL Life Sciences Ltd plunged to their lower circuit limit on 29 Dec 2025, reflecting intense selling pressure and a sharp decline of 4.89% in a single trading session. The stock closed at ₹12.65, marking its maximum permissible daily loss and signalling panic selling among investors amid subdued market participation and unfilled supply.

JFL Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company's standing in the Pharmaceuticals & Biotechnology sector.

Shares of JFL Life Sciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, faced intense selling pressure on 26 Dec 2025, hitting the lower circuit price limit of ₹13.30. The stock recorded its maximum permissible daily loss of 5.0%, reflecting a sharp decline amid unfilled supply and panic selling, significantly underperforming both its sector and the broader market indices.

JFL Life Sciences Ltd witnessed robust buying interest on 24 Dec 2025, hitting its upper circuit limit with a maximum daily gain of 4.76%. The stock closed at ₹15.40, marking a significant outperformance against its sector and broader market indices, driven by heightened investor participation and unfilled demand.

JFL Life Sciences Ltd witnessed a significant surge in trading activity on 23 Dec 2025, hitting its upper circuit price limit of ₹14.70, marking a maximum daily gain of 5.0%. This movement reflects robust buying interest in the stock within the Pharmaceuticals & Biotechnology sector, accompanied by a regulatory freeze on further transactions, resulting in unfilled demand and heightened market attention.

Shares of JFL Life Sciences Ltd surged to their upper circuit limit on 22 Dec 2025, reflecting robust buying interest and a maximum permissible daily gain of 5%. The stock outperformed its Pharmaceuticals & Biotechnology sector peers and broader market indices, signalling heightened investor enthusiasm despite a micro-cap market capitalisation of ₹45.86 crore.

JFL Life Sciences Ltd witnessed a significant surge in its share price on 19 Dec 2025, hitting the upper circuit limit of 13.35, marking a maximum daily gain of 4.71%. This movement was accompanied by robust buying interest and a notable rise in delivery volumes, reflecting heightened investor participation in the Pharmaceuticals & Biotechnology sector.

JFL Life Sciences Ltd witnessed a significant surge in trading activity on 18 Dec 2025, hitting its upper circuit price limit of ₹12.75. The stock recorded a maximum daily gain of 4.94%, outperforming its sector and broader market indices, driven by robust buying interest and a notable rise in delivery volumes.